Italfarmaco SpAs Givinostat, a small molecule histone deacetylase (HDAC) inhibitor in clinical testing against several forms muscular dystrophies, is also an option to treat heart failure with preserved ejection fraction (HFpEF), a form of congestive heart failure that affects 50% of heart failure patients.
ADVERTISEMENT
German researchers have identified a target to switch off intestinal acute graft-versus-host disease (GVHD), which occurs in about 50% of leukemia patients that have been given a allogeneic hematopoietic cell transplantation (allo-HCT).
Addex Therapeutics, a leading company in allosteric modulation-based drug discovery and development, announced today the appointment of Jean-Philippe Rocher, PhD, as Co-Head of Discovery and Member of the Executive Management, effective 1 June 2018.
The European Medicines Agency (EMA) has won a landmark battle about the amount of data from clinical dossiers that may be made public. The European Court of Justics (EJC) rejected the demand of three drug developers not to publish what they called confidential information under the EMAs transparency rules.
Selvita S.A., a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer.
Global health product development partnership FIND (Foundation for Innovative New Diagnostics) has announced four major diagnostics projects to combat antimicrobial resistance (AMR) in resource-poor settings.
In mid-November, the European Commission tabled the long-awaited review of its Bioeconomy Strategy and Action Plan. European Biotechnology spoke with Waldemar Kütt, Head of Unit Bioeconomy Strategy, about the development the bioeconomy has made since its launch in 2012 by the European Commission and the instruments needed to attract investments, make it circular, and create a stable policy environment for companies and investors.
A brand-new survey conducted by auditing and consulting firm PwC and Strategy& has found out that 80% of data protection-prone Germans would share their data in case of being diagnosed with cancer. The results show that cancer could act as a gate-opener to approaches in personalised medicine that depend on the accessiblity of patient data.
US and Dutch researchers have found that carcinogenic E. coli and B. fragilis versions in the gut of patients who developed precancerous polyps early in life trigger development of colon cancer by secreting proinflammatoy signals, depleting mucus and inducing DNA damage.
Using CRISPR-Cas 9 genome editing, US and German stem cell researchers have corrected clustered mutations in the dystrophin gene in heart mucle cells obtained from induced pluripotent stem cells of patients with Duchenne muscular dystrophy (DMD).